TRT denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Testosterone Replacement Therapy as Duplicate Therapy — and How to Appeal

Testosterone replacement therapy (TRT) encompasses several FDA-approved formulations — including injectable, topical, and implantable options — prescribed for hypogonadism. A "duplicate therapy" denial from UnitedHealthcare typically occurs when the plan's system detects that you are already receiving a medication it classifies as serving the same therapeutic purpose. In the TRT context this may occur when two testosterone products are on file simultaneously, or when TRT is flagged against another hormone-related therapy.

### Why This Denial Is Appealable

Duplicate-therapy flags are often triggered by automated pharmacy adjudication logic, not by a clinical review of your actual regimen. If your prescriber has a clinical reason to prescribe two formulations concurrently (for example, a transitional overlap, distinct routes for distinct purposes, or a formulary switch in progress), that rationale can overturn the denial. If the flag is simply an error — a prior fill that has been discontinued — correcting the record resolves the issue.

### Federal Appeal Framework

• Internal appeal: UHC must decide standard appeals within 30 days (pharmacy) and expedited appeals within 72 hours. Start with a formal written internal appeal.
• External review (ACA §2719): After exhausting internal appeals, you may request independent external review by an accredited IRO.
• ERISA §503: Employer-plan members have the right to full-and-fair review, including access to all criteria and the clinical rationale for denial.
• Timeline: External review requests must generally be filed within approximately four months of the final internal denial. Request expedited review if clinical urgency applies.

### Concrete Appeal Steps

1. Request UHC's denial rationale in writing, identifying the specific product flagged as the duplicate. 2. Confirm with your prescriber and pharmacy whether the conflicting medication is still active or has been discontinued. 3. If discontinued: submit pharmacy records showing discontinuation plus a prescriber note; ask UHC to reprocess. 4. If concurrent use is intentional: obtain a letter from your prescriber explaining the medical necessity of both products simultaneously. 5. File the internal appeal and escalate to external review if needed.

### Documentation to Gather

• Diagnosis confirmation: Lab results establishing hypogonadism diagnosis and prescriber notes documenting clinical symptoms.
• Current medication list: A complete, date-stamped medication list from your prescriber showing what is active versus discontinued.
• Pharmacy fill history: Evidence from your pharmacy showing whether the flagged duplicate has been filled recently.
• Prescriber medical-necessity letter: Explaining the clinical rationale if concurrent TRT products are genuinely both required.

### Criteria-Mapping Structure

Obtain UHC's published coverage policy for testosterone replacement therapy. Map each coverage criterion to chart evidence:

| UHC Policy Requirement | Supporting Chart or Pharmacy Evidence | |---|---| | [Copy each criterion from UHC coverage policy] | [Date, document, prescriber note] |

Also consult the FDA-approved prescribing label for the specific TRT product at DailyMed to confirm its approved indication and ensure the clinical record reflects the labeled use.